10x Genomics reported modest top-line growth in Q2 2026, driven by steady consumables usage despite declines in non-recurring license revenues from prior patent settlements. The company's integrated single cell and spatial analysis platform maintains a stable installed instrument base, supporting recurring consumables sales. A key development was the acquisition of Proteintech Genomics, expanding 10x’s multiomics offering into high-plex proteomic solutions, a strategic complement to its core microfluidics-enabled technologies. While operating losses persist due to continued R&D and integration costs, the company's financial position remains robust with strong liquidity. Navigating competitive pressures and sustaining innovation through acquisitions remain critical growth levers.